Literature DB >> 18088090

Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 receptor.

Alexander V Mayorov1, Minying Cai, Erin S Palmer, Matthew M Dedek, James P Cain, April R Van Scoy, Bahar Tan, Josef Vagner, Dev Trivedi, Victor J Hruby.   

Abstract

A variety of dicarboxylic acid linkers introduced between the alpha-amino group of Pro(6) and the -amino group of Lys(10) of the cyclic lactam alpha-melanocyte-stimulating hormone (alpha-MSH)-derived Pro(6)-D-Phe(7)/D-Nal(2')(7)-Arg(8)-Trp(9)-Lys(10)-NH2 pentapeptide template lead to nanomolar range and selective hMC3R agonists and antagonists. Replacement of the Pro(6) residue and the dicarboxylic acid linker with 2,3-pyrazine-dicarboxylic acid furnished a highly selective nanomolar range hMC3R partial agonist (analogue 12, c[CO-2,3-pyrazine-CO-D-Phe-Arg-Trp-Lys]-NH2, EC50 = 27 nM, 70% max cAMP) and an hMC3R antagonist (analogue 13, c[CO-2,3-pyrazine-CO-D-Nal(2')-Arg-Trp-Lys]-NH2, IC50 = 23 nM). Modeling experiments suggest that 2,3-pyrazinedicarboxylic acid stabilizes a beta-turn-like structure with the D-Phe/D-Nal(2') residues, which explains the high potency of the corresponding peptides. Placement of a Nle residue in position 6 produced a hMC3R/hMC5R antagonist (analogue 15, c[CO-(CH 2)2-CO-Nle-D-Nal(2')-Arg-Trp-Lys]-NH2, IC50 = 12 and 17 nM, respectively), similarly to the previously described cyclic gamma-melanocyte-stimulating hormone (gamma-MSH)-derived hMC3R/hMC5R antagonists. These newly developed melanotropins will serve as critical biochemical tools for elucidating the full spectrum of functions performed by the physiologically important melanocortin-3 receptor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18088090      PMCID: PMC2587288          DOI: 10.1021/jm070461w

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  73 in total

1.  Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist.

Authors:  Iyassu K Sebhat; William J Martin; Zhixiong Ye; Khaled Barakat; Ralph T Mosley; David B R Johnston; Raman Bakshi; Brenda Palucki; David H Weinberg; Tanya MacNeil; Rubana N Kalyani; Rui Tang; Ralph A Stearns; Randy R Miller; Constantin Tamvakopoulos; Alison M Strack; Erin McGowan; Doreen E Cashen; Jennifer E Drisko; Gary J Hom; Andrew D Howard; D Euan MacIntyre; Lex H T van der Ploeg; Arthur A Patchett; Ravi P Nargund
Journal:  J Med Chem       Date:  2002-10-10       Impact factor: 7.446

2.  Novel cyclic templates of alpha-MSH give highly selective and potent antagonists/agonists for human melanocortin-3/4 receptors.

Authors:  Malcolm J Kavarana; Dev Trivedi; Minying Cai; Jinfa Ying; Matthew Hammer; Christopher Cabello; Paolo Grieco; Guoxia Han; Victor J Hruby
Journal:  J Med Chem       Date:  2002-06-06       Impact factor: 7.446

3.  Arylpropionylpiperazines as antagonists of the human melanocortin-4 receptor.

Authors:  Wanlong Jiang; Fabio C Tucci; Caroline W Chen; Melissa Arellano; Joe A Tran; Nicole S White; Dragan Marinkovic; Joseph Pontillo; Beth A Fleck; Jenny Wen; John Saunders; Ajay Madan; Alan C Foster; Chen Chen
Journal:  Bioorg Med Chem Lett       Date:  2006-06-13       Impact factor: 2.823

4.  Novel 3D pharmacophore of alpha-MSH/gamma-MSH hybrids leads to selective human MC1R and MC3R analogues.

Authors:  Minying Cai; Alexander V Mayorov; Christopher Cabello; Magda Stankova; Dev Trivedi; Victor J Hruby
Journal:  J Med Chem       Date:  2005-03-24       Impact factor: 7.446

Review 5.  Neuropathic pain: a possible role for the melanocortin system?

Authors:  D H Vrinten; C J Kalkman; R A Adan; W H Gispen
Journal:  Eur J Pharmacol       Date:  2001-10-19       Impact factor: 4.432

6.  Potent and selective peptide agonists of alpha-melanotropin action at human melanocortin receptor 4: their synthesis and biological evaluation in vitro.

Authors:  M A Bednarek; T MacNeil; R Tang; R N Kalyani; L H Van der Ploeg; D H Weinberg
Journal:  Biochem Biophys Res Commun       Date:  2001-08-24       Impact factor: 3.575

7.  Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction.

Authors:  H Wessells; D Gralnek; R Dorr; V J Hruby; M E Hadley; N Levine
Journal:  Urology       Date:  2000-10-01       Impact factor: 2.649

8.  Melanocortin-5 receptor deficiency promotes defensive behavior in male mice.

Authors:  Caurnel Morgan; Ruth E Thomas; Roger D Cone
Journal:  Horm Behav       Date:  2004-01       Impact factor: 3.587

9.  Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor.

Authors:  D Lu; D Willard; I R Patel; S Kadwell; L Overton; T Kost; M Luther; W Chen; R P Woychik; W O Wilkison
Journal:  Nature       Date:  1994-10-27       Impact factor: 49.962

10.  Identification of 2-[2-[2-(5-bromo-2- methoxyphenyl)-ethyl]-3-fluorophenyl]-4,5-dihydro-1H-imidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model.

Authors:  Tricia J Vos; Andrei Caracoti; Jennifer L Che; Mingshi Dai; Cheryl A Farrer; Nancy E Forsyth; Stacey V Drabic; Robert A Horlick; Diana Lamppu; David L Yowe; Suresh Balani; Ping Li; Hang Zeng; Ingrid B J K Joseph; Luis E Rodriguez; Martin P Maguire; Michael A Patane; Christopher F Claiborne
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

View more
  6 in total

1.  Approaches to the rational design of selective melanocortin receptor antagonists.

Authors:  Victor J Hruby; Minying Cai; Joel Nyberg; Dhanasekaran Muthu
Journal:  Expert Opin Drug Discov       Date:  2011-03-24       Impact factor: 6.098

Review 2.  Melanotropins as drugs for the treatment of obesity and other feeding disorders: potential and problems.

Authors:  Minying Cai; Joel Nyberg; Victor J Hruby
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

3.  Utilize conjugated melanotropins for the earlier diagnosis and treatment of melanoma.

Authors:  Minying Cai; Zhonglin Liu; Hongchang Qu; Helen Fan; Zhiping Zheng; Victor J Hruby
Journal:  Eur J Pharmacol       Date:  2011-02-16       Impact factor: 4.432

4.  Solid-phase peptide head-to-side chain cyclodimerization: discovery of C(2)-symmetric cyclic lactam hybrid α-melanocyte-stimulating hormone (MSH)/agouti-signaling protein (ASIP) analogues with potent activities at the human melanocortin receptors.

Authors:  Alexander V Mayorov; Minying Cai; Erin S Palmer; Zhihua Liu; James P Cain; Josef Vagner; Dev Trivedi; Victor J Hruby
Journal:  Peptides       Date:  2010-08-03       Impact factor: 3.750

5.  Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 receptor.

Authors:  Hongchang Qu; Minying Cai; Alexander V Mayorov; Paolo Grieco; Morgan Zingsheim; Dev Trivedi; Victor J Hruby
Journal:  J Med Chem       Date:  2009-06-25       Impact factor: 7.446

6.  Demonstration of a Common DPhe7 to DNal(2')7 Peptide Ligand Antagonist Switch for Melanocortin-3 and Melanocortin-4 Receptors Identifies the Systematic Mischaracterization of the Pharmacological Properties of Melanocortin Peptides.

Authors:  Luis E Gimenez; Terry A Noblin; Savannah Y Williams; Satarupa Mullick Bagchi; Ren-Lei Ji; Ya-Xiong Tao; Claus B Jeppesen; Kilian W Conde-Frieboes; Tomi K Sawyer; Paolo Grieco; Roger D Cone
Journal:  J Med Chem       Date:  2022-04-11       Impact factor: 7.446

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.